Ur Metser

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8965309/publications.pdf

Version: 2024-02-01

78 papers	1,674 citations	257450 24 h-index	330143 37 g-index
80 all docs	80 docs citations	80 times ranked	2607 citing authors

#	Article	IF	Citations
1	The Role and Limitations of 18-Fluoro-2-deoxy-d-glucose Positron Emission Tomography (FDG-PET) Scan and Computerized Tomography (CT) in Restaging Patients with Hepatic Colorectal Metastases Following Neoadjuvant Chemotherapy: Comparison with Operative and Pathological Findings. Journal of Gastrointestinal Surgery, 2007, 11, 472-478.	1.7	149
2	Repeatability and reproducibility of MRI-based radiomic features in cervical cancer. Radiotherapy and Oncology, 2019, 135, 107-114.	0.6	112
3	Assessment of Tumor Recurrence in Patients With Colorectal Cancer and Elevated Carcinoembryonic Antigen Level: FDG PET/CT Versus Contrast-Enhanced 64-MDCT of the Chest and Abdomen. American Journal of Roentgenology, 2010, 194, 766-771.	2.2	71
4	18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkinâ€™s lymphoma as predictors of treatment outcome and survival. Annals of Nuclear Medicine, 2018, 32, 410-416.	2.2	64
5	Detection of Urothelial Tumors: Comparison of Urothelial Phase with Excretory Phase CT Urographyâ€"A Prospective Study. Radiology, 2012, 264, 110-118.	7.3	62
6	Association of Apparent Diffusion Coefficient with Disease Recurrence in Patients with Locally Advanced Cervical Cancer Treated with Radical Chemotherapy and Radiation Therapy. Radiology, 2016, 279, 158-166.	7.3	54
7	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. British Journal of Cancer, 2016, 115, 1186-1192.	6.4	50
8	68Ga PET Imaging in Patients With Neuroendocrine Tumors. Clinical Nuclear Medicine, 2018, 43, 802-810.	1.3	50
9	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	1.9	49
10	Convolutional neural networks for improving image quality with noisy PET data. EJNMMI Research, 2020, 10, 105.	2.5	47
11	Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on ¹⁸F-Fluoroazomyin Arabinoside Uptake. Journal of Nuclear Medicine, 2016, 57, 361-366.	5.0	42
12	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.8	42
13	A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. Radiotherapy and Oncology, 2016, 120, 519-525.	0.6	41
14	Quantitative ⁶⁸Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE. Journal of Nuclear Medicine, 2021, 62, 1406-1414.	5.0	40
15	Assessment of Urinary Tract Calculi With 64-MDCT: The Axial Versus Coronal Plane. American Journal of Roentgenology, 2009, 192, 1509-1513.	2.2	39
16	Fungal Liver Infection in Immunocompromised Patients: Depiction with Multiphasic Contrast-enhanced Helical CT. Radiology, 2005, 235, 97-105.	7.3	38
17	Comparison of 18F-FDG-PET/CT and 18F-FDG-PET/MR imaging in oncology: a systematic review. Annals of Nuclear Medicine, 2017, 31, 366-378.	2.2	38
18	Convolutional Neural Networks in Predicting Nodal and Distant Metastatic Potential of Newly Diagnosed Nonâ€“Small Cell Lung Cancer on FDG PET Images. American Journal of Roentgenology, 2020, 215, 192-197.	2.2	37

#	Article	IF	Citations
19	Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma. Seminars in Radiation Oncology, 2015, 25, 164-171.	2.2	34
20	Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology, 2022, 304, 566-579.	7.3	33
21	Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis. European Journal of Hybrid Imaging, 2021, 5, 24.	1.5	31
22	[¹⁸F]â€FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study. Cancer, 2017, 123, 2860-2866.	4.1	30
23	Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation. JCO Precision Oncology, 2018, 2, 1-8.	3.0	26
24	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸F-Fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 1253-1258.	5.0	24
25	Identification and Quantification of Peritoneal Metastases in Patients With Ovarian Cancer With Multidetector Computed Tomography. International Journal of Gynecological Cancer, 2011, 21, 1391-1398.	2.5	23
26	FDG-PET parameters predict for recurrence in anal cancer â€“ results from a prospective, multicentre clinical trial. Radiation Oncology, 2019, 14, 140.	2.7	22
27	Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry. Radiology, 2019, 290, 488-495.	7.3	22
28	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	21
29	The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2023, 26, 240-248.	3.9	21
30	18F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer. Annals of Nuclear Medicine, 2014, 28, 295-303.	2.2	20
31	MR Imaging Findings and Patterns of Spread in Secondary Tumor Involvement of the Uterine Body and Cervix. American Journal of Roentgenology, 2003, 180, 765-769.	2.2	19
32	FDG-PET/CT in abdominal post-transplant lymphoproliferative disease. British Journal of Radiology, 2016, 89, 20150844.	2.2	18
33	Benign Cutaneous and Subcutaneous Lesions on FDG-PET/CT. Seminars in Nuclear Medicine, 2017, 47, 352-361.	4.6	17
34	Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer. American Journal of Roentgenology, 2019, 212, 377-381.	2.2	17
35	How to Design AI-Driven Clinical Trials in Nuclear Medicine. Seminars in Nuclear Medicine, 2021, 51, 112-119.	4.6	17
36	68Ga-PSMA PET in prostate cancer: a systematic review andÂmeta-analysisÂof theÂobserver agreement. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1021-1029.	6.4	17

#	Article	IF	Citations
37	Effect of ¹⁸F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	7.3	16
38	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3702-3711.	6.4	15
39	Evaluation of Upper Urinary Tract Tumors With Portal Venous Phase MDCT: A Case-Control Study. American Journal of Roentgenology, 2011, 197, 424-428.	2.2	14
40	Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer. Clinical Nuclear Medicine, 2022, 47, 684-691.	1.3	14
41	FDG PET/CT Response Assessment Criteria for Patients with Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma at End of Therapy: A Multiparametric Approach. Nuclear Medicine and Molecular Imaging, 2016, 50, 46-53.	1.0	13
42	¹⁸F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer. American Journal of Roentgenology, 2018, 210, 635-640.	2.2	12
43	Measurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with 18F-Fluoroazomyin Arabinoside. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1202-1209.	0.8	12
44	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
45	Deep learning for whole-body medical image generation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3817-3826.	6.4	12
46	¹⁸F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. British Journal of Radiology, 2018, 91, 20170814.	2.2	10
47	Impact of ¹⁸F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. Radiology, 2022, 304, 600-608.	7.3	10
48	Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1012-1020.	6.4	9
49	Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA Network Open, 2018, 1, e182081.	5.9	8
50	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	1.9	8
51	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
52	CCTG HN.10: A phase II single-arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma (NCT03822897).. Journal of Clinical Oncology, 2020, 38, TPS6592-TPS6592.	1.6	7
53	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. American Journal of Hematology, 2022, 97, 583-591.	4.1	7
54	Ultra-low dose CT abdomen and pelvis for the detection of acute abdominal pathology in the emergency room: initial experience from an academic hospital. Emergency Radiology, 2021, 28, 15-21.	1.8	5

#	Article	IF	Citations
55	Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada. Frontiers in Oncology, 2021, 11, 722430.	2.8	5
56	Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up. Cancers, 2022, 14, 3105.	3.7	5
57	¹⁸F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. Journal of Nuclear Medicine, 2020, 61, 1615-1620.	5.0	4
58	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. Blood Advances, 2020, 4, 5762-5771.	5.2	3
59	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
60	Neuroendocrine Tumors. PET Clinics, 2021, 16, 353-364.	3.0	3
61	Cystic lesions of the pancreatico-biliary tree: A schematic MRI approach. Indian Journal of Radiology and Imaging, 2017, 27, 167-176.	0.8	3
62	The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 73-77.	1.1	3
63	Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial. Annals of Nuclear Medicine, 2017, 31, 153-162.	2.2	2
64	Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders. Nuclear Medicine Communications, 2020, 41, 34-39.	1.1	2
65	Elective neck dissection versus positron emission tomographyâ€“computed tomographyâ€“guided management of the neck in clinically nodeâ€negative early oral cavity cancer: A costâ€“utility analysis. Cancer, 2021, 127, 1993-2002.	4.1	2
66	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. Current Oncology, 2021, 28, 3251-3258.	2.2	2
67	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. Canadian Urological Association Journal, 2021, 16, .	0.6	2
68	Management of Wolffian adnexal tumors. International Journal of Gynecological Cancer, 2021, 31, 925-928.	2.5	1
69	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5553-5553.	1.6	1
70	Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Canadian Urological Association Journal, 2021, 16, .	0.6	1
71	Case â€“ 18F-DCFPyL-positron emission tomography/computed tomography (PET/CT) time of imaging. Canadian Urological Association Journal, 2020, 15, E376-E379.	0.6	1
72	Preliminary evaluation of 18F-FDG-PET/MRI for differentiation of serous from nonserous pancreatic cystic neoplasms: a pilot study. Nuclear Medicine Communications, 2020, 41, 1257-1264.	1.1	1

#	Article	IF	Citations
73	The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients. Langenbeck's Archives of Surgery, 2022, 407, 1677-1684.	1.9	1
74	Utility of 18F-FDG-PET/CT imaging in patients with recurrent gynecological malignancies prior to pelvic exenteration. International Journal of Gynecological Cancer, 2019, 29, 816-820.	2.5	0
75	Quantitative assessment of dynamic ¹⁸F-flumethycholine PET and dynamic contrast enhanced MRI in high risk prostate cancer. British Journal of Radiology, 2019, 92, 20180568.	2.2	0
76	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. Blood, 2016, 128, 4645-4645.	1.4	0
77	Preliminary results of a two stage phase II study of 18F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.. Journal of Clinical Oncology, 2019, 37, 250-250.	1.6	0
78	MRI classification and characterization of complex ovarian masses. , 0, , 6-20.		0